Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia

CompletedOBSERVATIONAL
Enrollment

97

Participants

Timeline

Start Date

April 3, 2013

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Chronic Myeloid Leukemia
Interventions
BEHAVIORAL

Interruption of the treatment by Imatinib

Trial Locations (19)

13273

Institut Paoli Calmette, Marseille

29285

Hôpital Morvan, Brest

31059

Hôpital Purpan, Toulouse

33076

Institut Bergonié, Bordeaux

33604

CHU de Bordeaux - Haut-Lévêque, Bordeaux

38043

Pôle de cancérologie, Grenoble

44035

CHU Hôtel-Dieu, Nantes

49033

CHU d'Angers, Angers

54500

CHU Brabois, Vandœuvre-lès-Nancy

59037

Hôpital Claude Huriez, Lille

67000

Hôpital Civil, Strasbourg

69374

Hôpital Edouard Herriot, Lyon

75475

Hôpital Saint Louis, Paris

75743

Hôpital Necker-Enfants Malades, Paris

78157

Centre Hospitalier de Versailles, Le Chesnay

85025

Centre Hospitalier de La Roche Sur Yon, La Roche-sur-Yon

86021

CHU de Poitiers, Poitiers

94000

Hôpital Henri-Mondor, Créteil

06202

CHU de Nice, Nice

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT02896829 - Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia | Biotech Hunter | Biotech Hunter